Laser-Ablated Gold Nanoparticles as Tunable Contrast Agents for Preclinical Imaging
Nanomaterials · 10.12.2025 · 15 (24) · 1851
DOI: 10.3390/nano15241851 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanomaterials, online erschienen am 10.12.2025. Verfasst von Yulia Finogenova und 9 weiteren Autor:innen. Beteiligte Einrichtung: N.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Economic Development of the Russian Federation: Grant Agreement from the Federal Budget in the form of a Subsidy to the Federal State Budgetary Ins….
Abstract (Originalsprache)
Femtosecond laser-ablated gold nanoparticles (AuNPs) offer a unique platform for developing novel cost-effective contrast agents due to their ultraclean, surfactant-free synthesis and precisely tunable surface properties. This study developed three computed tomography (CT) contrast agents from a single stock solution of laser-ablated AuNPs, functionalized with polyethylene glycol (PEG-2kDa, PEG-4kDa), or lipoic acid with bovine serum albumin (BSA). The primary objective was to evaluate the safety and functional efficacy of these coated AuNPs in healthy and tumor-bearing mice. After a single intravenous injection (690 ± 30 mg Au/kg), all formulations were well tolerated with no acute toxicity observed. PEGylated AuNPs demonstrated long blood half-life (18 ± 2 h for PEG-2kDa; 37 ± 2 h for PEG-4kDa), making them suitable for cardiovascular imaging up to 24 h post-injection. BSA-AuNPs had a rapid blood clearance (T1/2 = 2.8 ± 0.9 h), permitting cardiovascular assessment during the first 3 h, and provided intense, persistent contrast in abdominal organs, enabling liver imaging from 5 min and spleen imaging from 1 h post-injection. In a Ca755 mammary adenocarcinoma model, PEGylated AuNPs selectively accumulated in the tumor stroma and fibrous septa, allowing for precise tumor margin delineation and analysis of internal architecture. The findings establish that a single AuNP stock can be used to produce specialized contrast agents for specific imaging applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- N.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.
- Engineer and Physics Institute of Biomedicine, National Research Nuclear University MEPhI, Moscow 115409, Russia.
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Moscow 119991, Russia.
- The Loginov Moscow Clinical Scientific Center, Moscow 111123, Russia.
ORCID-Profile: Yulia Finogenova, Vsevolod Skribitsky, Alexey Lipengolts, Angelina Skribitskaya, Anton Kasianov, Kristina Shpakova, Artem Laktionov, Islam Sozaev, Anna Smirnova, Elena Grigorieva
Förderung
- Ministry of Economic Development of the Russian Federation: Grant Agreement from the Federal Budget in the form of a Subsidy to the Federal State Budgetary Ins…
Zitieren
APA
Finogenova, Y., Skribitsky, V., Lipengolts, A., Skribitskaya, A., Kasianov, A., Shpakova, K., Laktionov, A., Sozaev, I., Smirnova, A., & Grigorieva, E. (2025). Laser-Ablated Gold Nanoparticles as Tunable Contrast Agents for Preclinical Imaging. Nanomaterials, 15(24), 1851. https://doi.org/10.3390/nano15241851
Vancouver
Finogenova Y, Skribitsky V, Lipengolts A, Skribitskaya A, Kasianov A, Shpakova K, et al. Laser-Ablated Gold Nanoparticles as Tunable Contrast Agents for Preclinical Imaging. Nanomaterials. 2025;15(24):1851. doi:10.3390/nano15241851
BibTeX
@article{Finogenova2025,
author = {Finogenova, Yulia and Skribitsky, Vsevolod and Lipengolts, Alexey and Skribitskaya, Angelina and Kasianov, Anton and Shpakova, Kristina and Laktionov, Artem and Sozaev, Islam and Smirnova, Anna and Grigorieva, Elena},
title = {Laser-Ablated Gold Nanoparticles as Tunable Contrast Agents for Preclinical Imaging},
journal = {Nanomaterials},
year = {2025},
volume = {15},
number = {24},
pages = {1851},
doi = {10.3390/nano15241851}
}
EUVIMED